Citations (62)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
ShishuKant Suman, Rashmi Priya & Mythili Kameswaran. (2020) Induction of different cellular arrest and molecular responses in low EGFR expressing A549 and high EGFR expressing A431 tumor cells treated with various doses of 177Lu-Nimotuzumab. International Journal of Radiation Biology 96:9, pages 1144-1156.
Read now
Read now
Kai Teng, Yong Zhang, Xiaoyan Hu, Yihui Ding, Rui Gong & Li Liu. (2015) Nimotuzumab enhances radiation sensitivity of NSCLC H292 cells in vitro by blocking epidermal growth factor receptor nuclear translocation and inhibiting radiation-induced DNA damage repair. OncoTargets and Therapy 8, pages 809-818.
Read now
Read now
Camillo Porta, Palma Giglione, Wanda Liguigli & Chiara Paglino. (2015) Dovitinib (CHIR258, TKI258): Structure, Development and Preclinical and Clinical Activity. Future Oncology 11:1, pages 39-50.
Read now
Read now
Peter Hersey & Kavitha Gowrishankar. (2015) Pembrolizumab Joins the Anti-PD-1 Armamentarium in the Treatment of Melanoma. Future Oncology 11:1, pages 133-140.
Read now
Read now
Robert Pirker. (2015) What is the Best Strategy for Targeting EGF Receptors in Non-Small-Cell Lung Cancer?. Future Oncology 11:1, pages 153-167.
Read now
Read now
Udo Bode, Maura Massimino, Ferdinand Bach, Martina Zimmermann, Elena Khuhlaeva, Manfred Westphal & Gudrun Fleischhack. (2012)
Nimotuzumab treatment of malignant gliomas. Expert Opinion on Biological Therapy 12:12, pages 1649-1659.
Read now
Read now
Maura Massimino, Udo Bode, Veronica Biassoni & Gudrun Fleischhack. (2011) Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opinion on Biological Therapy 11:2, pages 247-256.
Read now
Read now
Christopher Fung & Jennifer R Grandis. (2010) Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opinion on Emerging Drugs 15:3, pages 355-373.
Read now
Read now
Catherine Lam, Eric Bouffet & Ute Bartels. (2009) Nimotuzumab in Pediatric Glioma. Future Oncology 5:9, pages 1349-1361.
Read now
Read now
Lieven Huang, Patrick De Baetselier & Rudi Beyaert. (2009) Targeting the EGF receptor ectodomain in the context of cancer. Expert Opinion on Therapeutic Targets 13:11, pages 1347-1361.
Read now
Read now
William Kells Boland & Gwyn Bebb. (2009) Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opinion on Biological Therapy 9:9, pages 1199-1206.
Read now
Read now
Fernando Rivera, Matilde Salcedo, Noelia Vega, Yolanda Blanco & Carlos López. (2009) Current situation of zalutumumab. Expert Opinion on Biological Therapy 9:5, pages 667-674.
Read now
Read now
Elizabeth A Hopper-Borge, Rochelle E Nasto, Vladimir Ratushny, Louis M Weiner, Erica A Golemis & Igor Astsaturov. (2009) Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opinion on Therapeutic Targets 13:3, pages 339-362.
Read now
Read now
Dimiter V Tassev & Nai-Kong V Cheung. (2009) Monoclonal antibody therapies for solid tumors. Expert Opinion on Biological Therapy 9:3, pages 341-353.
Read now
Read now
Sonia Garofalo, Roberta Rosa, Roberto Bianco & Giampaolo Tortora. (2008) EGFR-targeting agents in oncology. Expert Opinion on Therapeutic Patents 18:8, pages 889-901.
Read now
Read now
Articles from other publishers (49)
Maria Daniela Santi, Morgan Zhang, Naijiang Liu, Chi T. Viet, Tongxin Xie, Dane D. Jensen, Moran Amit, Huilin Pan & Yi Ye. (2023) Repurposing EGFR Inhibitors for Oral Cancer Pain and Opioid Tolerance. Pharmaceuticals 16:11, pages 1558.
Crossref
Crossref
Farzaneh Kordbacheh & Camile S. Farah. (2021) Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. Cancers 13:21, pages 5471.
Crossref
Crossref
Elias da Silva Santos, Karina Alexandre Barros Nogueira, Luiziana Cavalcante Costa Fernandes, Jéssica Roberta Pereira Martins, Alice Vitoria Frota Reis, José de Brito Vieira Neto, Ivanildo José da Silva Júnior, Claudia Pessoa, Raquel Petrilli & Josimar O. Eloy. (2021) EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles. International Journal of Pharmaceutics 592, pages 120082.
Crossref
Crossref
Shishu Kant Suman, Rohit Sharma & Chandan Kumar. 2021. Immunodiagnostic Technologies from Laboratory to Point-Of-Care Testing. Immunodiagnostic Technologies from Laboratory to Point-Of-Care Testing
61
74
.
Linlin Zhang, Barun Pradhan, Lili Guo, Fanlu Meng & Diansheng Zhong. (2019) EGFR exon 19‐deletion aberrantly regulate ERCC1 expression that may partly impaired DNA damage repair ability in non‐small cell lung cancer. Thoracic Cancer 11:2, pages 277-285.
Crossref
Crossref
Julie H. Selim, Shagufta Shaheen, Wei-Chun Sheu & Chung-Tsen Hsueh. (2019) Targeted and novel therapy in advanced gastric cancer. Experimental Hematology & Oncology 8:1.
Crossref
Crossref
Jose Alert, Ivon Chon, Jose Valdes, Ramon Ropero, Jesus Reno, Migdalia Perez, Mariuska Forteza & Debora Garcia. (2018) Long term survival in diffuse infiltrative brainstem gliomas in children and adolescents treated with radiatherapy and Nimotuzumab. International Journal of Radiology & Radiation Therapy 5:4.
Crossref
Crossref
Jose Alert, Ivon Chon, Jose Valdes, Ramon Ropero, Jesus Reno, Migdalia Perez, Mariuska Forteza & Debora Garcia. (2018) Long term survival in diffuse infiltrative brainstem gliomas in children and adolescents treated with radiotherapy and Nimotuzumab. International Journal of Radiology & Radiation Therapy 5:4.
Crossref
Crossref
Shima Moradi-Kalbolandi, Aysooda Hosseinzade, Malihe Salehi, Parnaz Merikhian & Leila Farahmand. (2018) Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER. Journal of Pharmacy and Pharmacology 70:7, pages 841-854.
Crossref
Crossref
Rodell T. Santuray, Daniel E. Johnson & Jennifer R. Grandis. (2018) New Therapies in Head and Neck Cancer. Trends in Cancer 4:5, pages 385-396.
Crossref
Crossref
Anna Kiseleva, Tim N. Beck, Ilya G. Serebriiskii, Hanqing Liu, Barbara Burtness & Erica A. Golemis. 2018. Molecular Determinants of Head and Neck Cancer. Molecular Determinants of Head and Neck Cancer
7
61
.
Daniela Lulli, Maria Luigia Carbone & Saveria Pastore. (2016) Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin. Oncotarget 7:30, pages 47777-47793.
Crossref
Crossref
Christopher C. Valley, Donna J. Arndt-Jovin, Narain Karedla, Mara P. Steinkamp, Alexey I. Chizhik, William S. Hlavacek, Bridget S. Wilson, Keith A. Lidke & Diane S. Lidke. (2015) Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer. Molecular Biology of the Cell 26:22, pages 4087-4099.
Crossref
Crossref
Leyanis Rodr?guez-Vera, Mayra Ramos-Suzarte, Eduardo Fern?ndez-S?nchez, Jorge Luis Soriano, Concepci?n Peraire Guitart, Gilberto Casta?eda Hern?ndez, Carlos O. Jacobo-Cabral, Niurys de Castro Su?rez & Helena Colom Codina. (2015) Semimechanistic model to characterize nonlinear pharmacokinetics of nimotuzumab in patients with advanced breast cancer. The Journal of Clinical Pharmacology 55:8, pages 888-898.
Crossref
Crossref
Mecca Madany, Tom M. Thomas, Lincoln Edwards & John S. Yu. 2015. Stem Cell Biology in Neoplasms of the Central Nervous System. Stem Cell Biology in Neoplasms of the Central Nervous System
139
166
.
Saveria Pastore, Daniela Lulli & Giampiero Girolomoni. (2014) Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. Archives of Toxicology 88:6, pages 1189-1203.
Crossref
Crossref
Woutjan Branderhorst, Erwin L.A. Blezer, Mischa Houtkamp, Ruud M. Ramakers, Jeroen H. van den Brakel, Henry Witteveen, Frans van der Have, Hugo A. Gratama van Andel, Brendan Vastenhouw, Chao Wu, Marijke Stigter-van Walsum, Guus A.M.S. van Dongen, Max A. Viergever, Wim K. Bleeker & Freek J. Beekman. (2014) Three-Dimensional Histologic Validation of High-Resolution SPECT of Antibody Distributions Within Xenografts. Journal of Nuclear Medicine 55:5, pages 830-837.
Crossref
Crossref
Dan Su, Shun-Chang Jiao, Li-Jie Wang, Wei-Wei Shi, Yan-Yan Long, Juan Li & Li Bai. (2013) Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. Tumor Biology 35:3, pages 2313-2318.
Crossref
Crossref
Ziwen Wang, Yujung Huang & Jiqiang Zhang. (2014) Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy. Cellular and Molecular Biology Letters 19:2.
Crossref
Crossref
Kamon Chaiyasit & Viroj Wiwanitkit. (2014) Acute reaction after administration of nimotuzumab: a concern. Journal of Acute Disease 3:2, pages 167.
Crossref
Crossref
Hanqing Liu, Jennifer R. Cracchiolo, Tim N. Beck, Ilya G. Serebriiskii & Erica A. Golemis. 2014. Molecular Determinants of Head and Neck Cancer. Molecular Determinants of Head and Neck Cancer
55
90
.
Maria Teresa Solomón, Julio César Selva, Javier Figueredo, José Vaquer, Carolina Toledo, Nelson Quintanal, Silvia Salva, Rafael Domíngez, José Alert, Jorge Juan Marinello, Mauricio Catalá, Martha González Griego, Juan Antonio Martell, Patricia Lorenzo Luaces, Javier Ballesteros, Niurys de-Castro, Ferdinand Bach & Tania Crombet. (2013) Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. BMC Cancer 13:1.
Crossref
Crossref
Wataru Okamoto, Takayuki Yoshino, Toshiaki Takahashi, Isamu Okamoto, Shinya Ueda, Asuka Tsuya, Narikazu Boku, Kazuto Nishio, Masahiro Fukuoka, Nobuyuki Yamamoto & Kazuhiko Nakagawa. (2013) A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 72:5, pages 1063-1071.
Crossref
Crossref
Feng Wen, Ruilei Tang, Yaxiong Sang, Meng Li, Qiancheng Hu, Zedong Du, Yi Zhou, Pengfei Zhang, Xiaofeng He & Qiu Li. (2013)
Which is false: Oxaliplatin or fluoropyrimidine? An analysis of patients with
KRAS
wild‐type metastatic colorectal cancer treated with first‐line epidermal growth factor receptor monoclonal antibody
. Cancer Science 104:10, pages 1330-1338.
Crossref
Crossref
Dirk Strumberg, Beate Schultheis, M. E. Scheulen, R. A. Hilger, J. Krauss, N. Marschner, F. Lordick, F. Bach, D. Reuter, L. Edler & K. Mross. (2010) Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Investigational New Drugs 30:3, pages 1138-1143.
Crossref
Crossref
Chengyuan Ma, Yang Li, Zhixin Li, Haiyan Huang, Kan Xu, Haiyang Xu, Jieying Bai, Xiao Li & Gang Zhao. (2012) Synthesis and purification of a toxin-linked conjugate targeting epidermal growth factor receptor in Escherichia coli. Protein Expression and Purification 83:1, pages 1-7.
Crossref
Crossref
Woody Han & Hui-Wen Lo. (2012) Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations. Cancer Letters 318:2, pages 124-134.
Crossref
Crossref
Benoit You & Eric X. Chen. (2012) Anti-EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab. The Journal of Clinical Pharmacology 52:2, pages 128-155.
Crossref
Crossref
Ajay Matta & Ranju Ralhan. 2012. Controversies in Oral Cancer. Controversies in Oral Cancer
1
16
.
Keith D. Hunter & Robert Bolt. 2012. Biotargets of Cancer in Current Clinical Practice. Biotargets of Cancer in Current Clinical Practice
19
59
.
Benoit You, Anthony Brade, Joao M. Magalhaes, Lillian L. Siu, Amit Oza, Sonya Lovell, Lisa Wang, David W. Hedley, Leonardo V. Nicacio & Eric X. Chen. (2010) A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. Investigational New Drugs 29:5, pages 996-1003.
Crossref
Crossref
Vinochani Pillay, Hui K. Gan & Andrew M. Scott. (2011) Antibodies in oncology. New Biotechnology 28:5, pages 518-529.
Crossref
Crossref
María Elena Mateos, Eduardo López‐Laso, Lucía Izquierdo, Juan Luis Pérez‐Navero, Sonia García & Cruces Garzás. (2011) Response to nimotuzumab in a child with a progressive diffuse intrinsic pontine glioma. Pediatrics International 53:2, pages 261-263.
Crossref
Crossref
Bing-Bing Yang, Peggy Lum, Alin Chen, Rosalin Arends, Lorin Roskos, Brian Smith & Juan José Pérez Ruixo. (2010) Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab. Clinical Pharmacokinetics 49:11, pages 729-740.
Crossref
Crossref
S. Jelic, I. Popov, V. H. Schartinger & G. M. Sprinzl. (2010) Head and neck cancer: a step forward. memo - Magazine of European Medical Oncology 3:2, pages 85-89.
Crossref
Crossref
Federico Rojo, Elías Gracias, Nadia Villena, Teresa Cruz, Josep Maria Corominas, Irene Corradino, Mercedes Cedeño, Clara Campas, Marta Osorio, Normando Iznaga, Beatriz Bellosillo, Ana Rovira, Silvia Marsoni, Pere Gascon, Sergio Serrano, Cristiana Sessa, Tania Crombet & Joan Albanell. (2010) Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study. Clinical Cancer Research 16:8, pages 2474-2482.
Crossref
Crossref
N. Boku. (2010) Current Status and Problems in Development of Molecular Target Agents for Gastrointestinal Malignancy in Japan. Japanese Journal of Clinical Oncology 40:3, pages 183-187.
Crossref
Crossref
Mikkel Wandahl Pedersen, Helle Jane Jacobsen, Klaus Koefoed, Adam Hey, Charles Pyke, John Sørensen Haurum & Michael Kragh. (2010) Sym004: A Novel Synergistic Anti–Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy. Cancer Research 70:2, pages 588-597.
Crossref
Crossref
Issa J. Dahabreh, Helena Linardou, Fotios Siannis, Paris Kosmidis, Dimitrios Bafaloukos & Samuel Murray. (2010)
Somatic
EGFR
Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
. Clinical Cancer Research 16:1, pages 291-303.
Crossref
Crossref
Doris R. Siwak, Mark Carey, Bryan T. Hennessy, Catherine T. Nguyen, Mollianne J. McGahren Murray, Laura Nolden & Gordon B. Mills. (2010) Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges. Journal of Oncology 2010, pages 1-20.
Crossref
Crossref
Roberto Bianco, Teresa Gelardi, Sonia Garofalo, Roberta Rosa & Giampaolo Tortora. 2010. Macromolecular Anticancer Therapeutics. Macromolecular Anticancer Therapeutics
407
436
.
Jed A Katzel, Michael P Fanucchi & Zujun Li. (2009) Recent advances of novel targeted therapy in non-small cell lung cancer. Journal of Hematology & Oncology 2:1.
Crossref
Crossref
J. Lamoril, N. Ameziane, J.-C. Deybach, P. Bouizegar?ne & M. Bogard. (2009) KRAS et cancer colorectal?: un pas de g?ant vers la m?decine personnalis?e. Immuno-analyse & Biologie Sp?cialis?e 24:4, pages 196-209.
Crossref
Crossref
Helena Linardou, Issa J. Dahabreh, Dimitrios Bafaloukos, Paris Kosmidis & Samuel Murray. (2009) Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nature Reviews Clinical Oncology 6:6, pages 352-366.
Crossref
Crossref
Tianhong Li & Roman Perez-Soler. (2009) Skin toxicities associated with epidermal growth factor receptor inhibitors. Targeted Oncology 4:2, pages 107-119.
Crossref
Crossref
Vinochani Pillay, Layal Allaf, Alexander L. Wilding, Jacqui F. Donoghue, Naomi W. Court, Steve A. Greenall, Andrew M. Scott & Terrance G. Johns. (2009) The Plasticity of Oncogene Addiction: Implications for Targeted Therapies Directed to Receptor Tyrosine Kinases. Neoplasia 11:5, pages 448-IN2.
Crossref
Crossref
Mikako Ogawa, Nobuyuki Kosaka, Michelle R. Longmire, Yasuteru Urano, Peter L. Choyke & Hisataka Kobayashi. (2009)
Fluorophore−Quencher Based Activatable Targeted Optical Probes for Detecting
in Vivo
Cancer Metastases
. Molecular Pharmaceutics 6:2, pages 386-395.
Crossref
Crossref
Elisa Vigna, Giovanni Pacchiana, Massimiliano Mazzone, Cristina Chiriaco, Lara Fontani, Cristina Basilico, Selma Pennacchietti & Paolo M. Comoglio. (2008) “Active” Cancer Immunotherapy by Anti-Met Antibody Gene Transfer. Cancer Research 68:22, pages 9176-9183.
Crossref
Crossref
Helena Linardou, Issa J Dahabreh, Dimitra Kanaloupiti, Fotios Siannis, Dimitrios Bafaloukos, Paris Kosmidis, Christos A Papadimitriou & Samuel Murray. (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. The Lancet Oncology 9:10, pages 962-972.
Crossref
Crossref